Alternative routine for reporting chiral amphetamine test results in assessment of attention‐deficit/hyperactivity disorder medication: experiences from 2013 to 2023
Drug Testing and Analysis · 2025
DOI: 10.1002/dta.3690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Anders Helander und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Amphetamine, Substance Abuse Detection. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This study evaluated an alternative routine for reporting urinary chiral amphetamine results in assessment of attention‐deficit/hyperactivity disorder (ADHD) treatment with amphetamine medications and for detecting side‐use of illicit racemic amphetamine. Currently in Sweden, only enantiopure d‐ amphetamine‐based ADHD medications (lisdexamphetamine dimesylate and dexamphetamine sulfate) are approved. It is therefore unsuitable to express the chiral result as the l / d‐ ratio, as before, because l‐ amphetamine should not be present provided treatment compliance. A new routine for LC‐MS/MS chiral amphetamine testing was therefore introduced in 2020, whereby the relative proportion (%) of l‐ amphetamine and the total amphetamine and creatinine concentrations are reported. Evaluation of the new routine on 24,354 results from 2013 to 2023 revealed that it was useful to distinguish ADHD medication adherence from illicit drug use as the source for a positive test. The l‐ amphetamine proportion also reflected the enantiomeric content of the medications used. Overall, most results confirmed adherence to ADHD medication, as the l‐ amphetamine percentage was 40% l‐ amphetamine) in 8.3%–14.5% of cases. In conclusion, this study demonstrated the clinical value and utility of a new routine for reporting urinary chiral amphetamine results to differentiate adherence to ADHD medication from illicit drug use. Unlike the l/d‐ amphetamine ratio, it considers differences in total amphetamine concentration and urine dilution, factors that can affect the interpretation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Anders Helander
Zitieren
APA
Helander, A., Andersson, A., & Villén, T. (2025). Alternative routine for reporting chiral amphetamine test results in assessment of attention‐deficit/hyperactivity disorder medication: experiences from 2013 to 2023. Drug Testing and Analysis. https://doi.org/10.1002/dta.3690
Vancouver
Helander A, Andersson A, Villén T. Alternative routine for reporting chiral amphetamine test results in assessment of attention‐deficit/hyperactivity disorder medication: experiences from 2013 to 2023. Drug Testing and Analysis. 2025. doi:10.1002/dta.3690
BibTeX
@article{Helander2025,
author = {Helander, Anders and Andersson, Annika and Villén, Tomas},
title = {Alternative routine for reporting chiral amphetamine test results in assessment of attention‐deficit/hyperactivity disorder medication: experiences from 2013 to 2023},
journal = {Drug Testing and Analysis},
year = {2025},
doi = {10.1002/dta.3690}
}
EUVIMED